Close Menu

NEW YORK (360Dx) – Swiss diagnostics firm ProteoMedix is pursuing the CE-IVD mark for its proteomic prostate cancer test.

The company earlier this year raised CHF 5.2 million ($5.3 million) in equity funding to finance its development and commercialization efforts and is currently planning a prospective clinical trial for the test, said CEO Ralph Schiess.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.